Description
INTRODUCTION
Clindamycin is used primarily to treat infections caused by susceptible anaerobic bacteria, including infections of the respiratory tract, skin and soft tissue infections, and peritonitis.In patients with hypersensitivity to penicillins, clindamycin may be used to treat infections caused by susceptible aerobic bacteria as well. It is also used to treat bone and joint infections, particularly those caused by Staphylococcus aureus. Topical application of clindamycin phosphate can be used to treat mild to moderate acne.
FUNCTION
Clindamycin is used primarily to treat infections caused by susceptible anaerobic bacteria, including infections of the respiratory tract, skin and soft tissue infections, and peritonitis.In patients with hypersensitivity to penicillins, clindamycin may be used to treat infections caused by susceptible aerobic bacteria as well. It is also used to treat bone and joint infections, particularly those caused by Staphylococcus aureus. Topical application of clindamycin phosphate can be used to treat mild to moderate acne.
FUNCTION
Clindamycin is used primarily to treat infections caused by susceptible anaerobic bacteria, including infections of the respiratory tract, skin and soft tissue infections, and peritonitis.In patients with hypersensitivity to penicillins, clindamycin may be used to treat infections caused by susceptible aerobic bacteria as well. It is also used to treat bone and joint infections, particularly those caused by Staphylococcus aureus. Topical application of clindamycin phosphate can be used to treat mild to moderate acne.
| Item | Specification | Test Results |
| Characteristics | White crystalline powder | Complies |
| Identification | Positive | Positive |
| Specific Optical Rotation | 40Mg/ml water solution +135~+150° | +145° |
| pH | 0.1g/ml water solution pH3.0~5.0 | 4.2 |
| Water | Between 3.0~6.0% | 4.20% |
| Sulphated Ash | ≤0.5% | 0.05% |
| Related Compounds | 7-Epiclindamycin≤4.0% | 0.50% |
| Clindamycin B≤2.0% | 0.30% | |
| Other Individual related compound≤1.0 | 0.50% | |
| Total of all related compounds≤6.0% | 1.80% | |
| Assay | ≥98.0% | 99.35% |
| Conclusion | The result conforms the standard | |
